QUOTE AND NEWS
StreetInsider.com  Nov 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/China+Medical+%28CMED%29+Posts+Q2+EPS+of+%240.10%3B+Guides+Below+Estimates/5125184.html for the full story.
PR Newswire  Nov 19  Comment 
BEIJING, Nov. 19 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today
PR Newswire  Nov 2  Comment 
BEIJING, Nov. 2 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today
PR Newswire  Sep 30  Comment 
BEIJING, Sept. 30 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in- vitro diagnostic products, today
PR Newswire  Sep 30  Comment 
BEIJING, Sept. 30 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 


 
TOP CONTRIBUTORS
CMED AT A GLANCE
 
 
 
 
 
 
 
 

Business

For some time the company focused on marketing its HIFU (High Intensive Focused Ultrasound) product which is used to treat various tumors. As the system became widely accepted in China, the opportunity to sell more units domestically dwindled. But rather than accept a slowing growth trajectory, management began exploring opportunities to sell their products outside of the mainland. At the same time, an acquisition in early 2007 allowed the company to step into the diagnostic equipment business, effectively re-tooling the company’s path and core business.

Nearly a year after the acquisition, the new FISH product line (Fluorescent In Situ Hybridization) now accounts for a large portion of the company’s revenues. CMED has spent the last several months aggressively building the installed base of machines across the country.

It will not run into the same issues it faced with the therapy systems because the FISH product line uses a significant amount of reagents to perform the tests. These reagents now provide the company with a stable, reliable revenue stream and are a very profitable part of the company’s business. With gross margins at nearly 80% for the consumable products, the company should continue to benefit from the growing number of diagnostic machines being used.[1]

Valuation

The company has a March fiscal year end and is expected to report $1.52 for the full 2008 year. Looking toward next year, the consensus estimates are for growth of 50% to $2.28 per share. While these estimates are not guaranteed in any way, it seems very attractive to be able to pick up a company growing at 50% in a stable market for less than 20 times next years earnings.

Trends and Forces

Geographic Reach

CMED’s primary market is China, but the geographic reach of the company is beginning to expand. With positive announcements in Korea and potential Japan and Russian deployments, the addressable market could quickly ramp higher. While it would likely take several quarters to grow the installed equipment base to a level that generated strong reagent sales, the long-term fundamentals point to some very exciting potential growth initiatives.

Acquisitions

future acquisitions are expected to be a key part of the company’s growth strategy. Management has proven its ability to seek and purchase new business lines which enable its sales team to leverage their relationships by selling new products to many of the same clients. In January, the company announced the purchase of Beijing BioEkon, which is a small diagnostic company. The purchase brings a new automated diagnostic system into the suite of products offered and should propel reagent sales even further. Additional acquisitions should be expected over the next several quarters.





References

  1. http://zachstocks.com/2008/03/china-medical-tech-cmed-transition-is-well-underway/
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki